R_A_Vishwakarma Profile Banner
Ram Vishwakarma Profile
Ram Vishwakarma

@R_A_Vishwakarma

Followers
898
Following
46
Media
1
Statuses
3K

Organic Chemist (Drug Discovery & Glycobiology) at CSIR, Earlier at CSIR-IIIM Jammu as Director, Piramal Healthcare Mumbai, NII New Delhi & Cambridge University

New Delhi
Joined May 2009
Don't wanna be here? Send us removal request.
@davidrliu
David R. Liu
8 days
Today in @Nature we report a new prime editing strategy that can rescue a common cause of many genetic diseases in a disease-agnostic manner. This approach converts a redundant endogenous tRNA into an optimized suppressor tRNA, enabling a single prime edit to rescue premature
33
383
1K
@NatRevDrugDisc
Nature Reviews Drug Discovery
10 days
FDA approves 100th small-molecule kinase inhibitor https://t.co/VjvGosLZ8f From the landmark approval of the anticancer drug imatinib almost a quarter century ago, our latest news feature analyses trends in the field of kinase inhibitors, now one of the major drug classes
0
55
154
@R_A_Vishwakarma
Ram Vishwakarma
21 days
A biochemical code linking chemical RNA modification to extracellular transport - a framework to study the function of extracellular RNAs in the nervous system and beyond | bioRxiv
Tweet card summary image
biorxiv.org
RNAs move through the extracellular space to transmit information between cells, including mammalian neurons, yet how specific RNAs are channeled into these extracellular routes is unknown. Using...
0
1
1
@NatRevDrugDisc
Nature Reviews Drug Discovery
22 days
FDA approves PDE4 inhibitor for idiopathic pulmonary fibrosis https://t.co/fQ45ZBFmA4 Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
0
12
37
@R_A_Vishwakarma
Ram Vishwakarma
23 days
A new platform for targeted delivery of drugs (biologics and nucleic acid therapies) through blood-brain barrier for neurological diseases
@BiotechTV
BiotechTV
24 days
š‚šØš¦š©ššš§š² ššžš°š¬: @Roche will pay @ManifoldBio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video: https://t.co/zGchJCPMjr
0
0
2
@EricTopol
Eric Topol
24 days
We keep getting better at controlling the immune system, with big implications for treating diseases 1. cGAS delivery via mRNA/nanoparticle revs up cancer immunotherapy https://t.co/AnNHe83M0r 2. Off-the-shelf CAR-T as good as patient-specific for lymphoma
6
71
280
@R_A_Vishwakarma
Ram Vishwakarma
23 days
Inflammation and Atherosclerosis: IL-1b, IL6 inhibitors. ColchicineĀ has emerged as the first anti-inflammatory drug approved for ASCVD prevention, with consistent benefits in LoDoCo, COLCOT, and LoDo trials
@FCademartiri
Dr. Filippo Cademartiri
25 days
šŸ”„Ā Inflammation: The Next Frontier in Atherosclerosis Therapy A new comprehensive review byĀ Peter LibbyĀ andĀ Oliver SoehnleinĀ (Immunity, 2025) revisits one of the most powerful ideas in cardiovascular medicine:Ā atherosclerosis is an inflammatory disease — and inflammation is now
0
0
1
@R_A_Vishwakarma
Ram Vishwakarma
28 days
Enduring value of immunization against respiratory viruses (Covid-19, RSV, Influenza) as a cornerstone of preventive care, supporting rigorous, evidence-based vaccine deployment. Spreading Anti-vaccine misinformation is dangerous for public health | NEJM
Tweet card summary image
nejm.org
Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunizati...
0
0
0
@JaredEMoskowitz
Jared Moskowitz
29 days
This is why we must restore all cancer funding.
@Rainmaker1973
Massimo
30 days
A single dose of a new cancer drug made a brain tumor almost disappear – in just five days. Doctors at Massachusetts General Hospital reported ā€œdramatic and rapidā€ tumor regression in the first patients treated with a next-generation form of CAR T-cell therapy for glioblastoma,
1K
19K
143K
@R_A_Vishwakarma
Ram Vishwakarma
1 month
Avidity Biosciences is developing drugs that use an emerging technology known as antibody oligonucleotide conjugates to deliver RNA treatment to muscles. - WSJ
Tweet card summary image
wsj.com
The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
0
0
3
@drwilliamwallac
William A. Wallace, Ph.D.
1 month
MIT found that the amino acid cysteine boosts stem cell repair by 30% via immune signals, healing radiation, or chemo damage. This research is the first to pinpoint a single nutrient that directly boosts the gut's regenerative capacity. Note that this was mechanistic rodent
26
166
740
@R_A_Vishwakarma
Ram Vishwakarma
1 month
Diversity of Interferon-independent antiviral defenses that mammalian hosts utilize to block viral infection | Journal of Virology
Tweet card summary image
journals.asm.org
Interferons (IFNs) are classified into three groups based on the different receptors they bind and have been reviewed in detail elsewhere (1–4). Here, we will focus on discussing the type I IFN...
0
0
0
@R_A_Vishwakarma
Ram Vishwakarma
1 month
Genetic studies reveal that polyunsaturated lipids do more than simply increase the fluidity of the cell membrane
Tweet card summary image
elifesciences.org
Genetic studies reveal that polyunsaturated lipids do more than simply increase the fluidity of the cell membrane.
0
0
0
@R_A_Vishwakarma
Ram Vishwakarma
1 month
Interesting new perspective and synthesis of ideas which were long suspected and perhaps obvious - The Hunt for the World’s Oldest Story | The New Yorker
Tweet card summary image
newyorker.com
From thunder gods to serpent slayers, scholars are reconstructing myths that vanished millennia ago. How much further can we go—and what might we find?
0
0
0
@maxhodak_
Max Hodak
1 month
Very excited that the clinical trial results for our PRIMA retinal prosthesis are published today in the New England Journal of Medicine! This is the first time that patients who are blind due to photoreceptor loss have been able to intuitively see again.
58
220
2K
@R_A_Vishwakarma
Ram Vishwakarma
1 month
The New England Journal of Medicine Reports Science Corp.’s PRIMA BCI Implant Restores Functional Central Vision to Patients with Geographic Atrophy Caused By Age-Related Macular Degeneration
Tweet card summary image
science.xyz
Science Corporation is a clinical-stage medical technology company.
0
0
0
@MarkOldhamMD
Mark Oldham
1 month
ElecsysĀ® pTau181 by Roche The first FDA-cleared blood test for use in primary care to rule out Alzheimer’s-related amyloid pathology https://t.co/diyk9tSRDn
3
45
147